Delaying Alzheimer Disease Symptoms With Anti-Inflammatory Drugs
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00065169|
Recruitment Status : Completed
First Posted : July 18, 2003
Last Update Posted : May 4, 2017
|Condition or disease||Intervention/treatment|
|Alzheimer Disease Dementia||Drug: Celecoxib|
AD is one of the most common mental disorders of late life. Preliminary studies indicate that anti-inflammatory drugs may attenuate or prevent AD symptoms, but efficacy trials are needed.
Participants in this study will be randomly assigned to receive either celecoxib or placebo for 18 months. Participants will undergo positron emission tomography (PET) and magnetic resonance imaging (MRI) scans of the brain. Routine laboratory blood tests, cognitive tests, and an electrocardiogram (ECG) will be performed. Participants will also be screened for Parkinson disease. Follow-up testing will be conducted at specific intervals following the study.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||138 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Anti-Inflammation in AD: PET Imaging Supplement|
|Study Start Date :||November 2000|
|Primary Completion Date :||November 2005|
|Study Completion Date :||November 2005|
U.S. FDA Resources
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00065169
|United States, California|
|UCLA Neuropsychiatric Institute|
|Los Angeles, California, United States, 90024|